RHYTHM PHARMACEUTICALS INC's ticker is RYTM and the CUSIP is 76243J105. A total of 147 filers reported holding RHYTHM PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,836,338 | -63.1% | 80,102 | -71.3% | 0.01% | -53.3% |
| Q1 2023 | $4,973,043 | +934.5% | 278,758 | +1588.6% | 0.03% | +900.0% |
| Q4 2022 | $480,713 | -82.4% | 16,508 | -85.2% | 0.00% | -80.0% |
| Q3 2022 | $2,732,000 | +571.3% | 111,511 | +13.7% | 0.02% | +650.0% |
| Q2 2022 | $407,000 | +178.8% | 98,091 | +569.1% | 0.00% | +100.0% |
| Q4 2021 | $146,000 | -30.5% | 14,661 | +51.2% | 0.00% | -66.7% |
| Q3 2020 | $210,000 | -34.4% | 9,694 | -30.4% | 0.00% | -50.0% |
| Q4 2019 | $320,000 | +58.4% | 13,919 | +48.8% | 0.01% | +50.0% |
| Q3 2019 | $202,000 | -27.3% | 9,352 | -25.9% | 0.00% | -20.0% |
| Q2 2019 | $278,000 | +1.8% | 12,622 | +44.5% | 0.01% | -64.3% |
| Q2 2018 | $273,000 | +1087.0% | 8,735 | +642.8% | 0.01% | +1300.0% |
| Q1 2018 | $23,000 | -73.6% | 1,176 | -60.7% | 0.00% | -80.0% |
| Q4 2017 | $87,000 | – | 2,992 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| COMMODORE CAPITAL LP | 2,075,000 | $47,569,375 | 5.56% |
| NEA Management Company, LLC | 2,909,956 | $66,710,741 | 5.15% |
| Opaleye Management Inc. | 653,000 | $14,970,025 | 4.87% |
| Frazier Life Sciences Management, L.P. | 2,371,304 | $54,362,144 | 3.61% |
| VR Adviser, LLC | 1,090,000 | $24,988,250 | 2.63% |
| RA Capital Management | 5,676,067 | $130,123,836 | 2.56% |
| Samsara BioCapital, LLC | 345,293 | $7,915,842 | 2.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 260,537 | $5,972,811 | 1.81% |
| Logos Global Management LP | 400,000 | $9,170,000 | 1.22% |
| Cormorant Asset Management, LP | 850,000 | $19,486,250 | 1.14% |